While at OncoQuest, he also led the regulatory effort for their lead product, oregovomab, to enter a Phase 3 study in combination with chemotherapy for front-line ovarian cancer, as well as for other early combination studies with checkpoint inhibitors, PARP inhibitors, and other immune adjuvants. where he built and led a multidisciplinary team to develop a range of immunotherapeutic oncology products. Bayever was Chief Medical Officer of OncoQuest Pharmaceuticals Inc. Bayever has over two decades experience in the biopharmaceutical industry developing small molecule oncology drugs and biologics. Somaiya received a Bachelor of Arts degree in Biology and Neuroscience from New York University.ĭr. He launched his Wall Street career as a research analyst at Morgan Stanley and Prudential Securities and was recognized as the "Best on the Street" by The Wall Street Journal for his coverage on biotechnology in 2006, 20. Ltd., Piper Jaffray Companies and Thomas Weisel Partners Group, Inc. He was Managing Director and Head of Biotechnology Research at BMO Capital Markets, and also served as a Managing Director and Equity Analyst at Nomura Securities Co. Somaiya spent over 20 years on Wall Street where he conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. During his nearly four years at TCR2, he led the company’s finance and public company reporting as well as business development and investor relations functions.
Most recently, he was Chief Financial Officer of TCR2 Therapeutics where he successfully navigated the company through its IPO and two follow-on financings, raising more than $350 million. Somaiya has over two decades of experience in finance and biotechnology. Mr Germano received his Bachelor of Sciece degree at the Albany College of Pharmacy and Health Sciences.
He continues to serve on the Advisory Board of the Healthcare Businesswomen's Association and is a Director of Sage Therapeutics (NASDAQ:SAGE) and The Medicines Company (NASDAQ:MDCO). He has been a member of the Group of Fifty (G50) and served on the Board of the Biotechnology Innovation Organization, where he was a member of the Executive Committee. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals including President of Wyeth U.S., President of Global Pharmaceutical and Women's Healthcare Business and Executive Vice President of the Vaccines Business. Previously, he was President and General Manager of Pfizer's Specialty Care, Vaccines and Oncology business units. Germano led Pfizer's Global Innovative Pharmaceutical Business, cultivating a $14 billion operation and guiding the development of an extensive portfolio of products in the cardiovascular, immunology, metabolic disease, neuroscience and rare disease areas. Germano has held multiple high-level roles at some of the world's largest and most innovative companies, including Pfizer, Johnson & Johnson and Wyeth. Narayanan said the company is confident of achieving $250 US sales in FY23.ĭon’t miss out on ET Prime stories! Get your daily dose of business updates on WhatsApp.Geno is a 30-year veteran of the pharmaceutical and Life Sciences industry and was most recently President of Intrexon, a leader in the application of synthetic biology across a broad range of market segments. The company plans to launch 4-5 products on a quarterly basis.Īnanthnarayanan said the acquisition business is expected to generate about $12 million - $14 million sales on a quarterly basis.Īnanthanaryanan said the fourth quarter could see a rollover of high cost raw materials and inventory. "We are also on track to launching products as we indicated from Q1FY23 onwards," Ananthnarayanan said.
#Endo pharma slalom full#
"The green shoots are coming up, the business has started seeing growth, we have been able to retain market share and seeing new contracts being signed," Ananthanarayanan said.Īnanthanarayanan said the Chestnut Ridge facility which came with the acquisition of Endo portfolio has successfully completed a USFDA inspection with 2 minor observationsĪnanthnarayanan said the full sales benefit of the acquired portfolio will be seen from the fourth quarter.
0 kommentar(er)
